Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(50.0%)
N/A
2(50.0%)
4Total
Phase 4(2)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03024684Phase 4Active Not Recruiting

Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

Role: collaborator

NCT01732354Completed

Study for Consolidation Period of Chronic Hepatitis B

Role: lead

NCT02762448Withdrawn

Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas

Role: lead

NCT03135964Not ApplicableCompleted

The Study of Wound Dressings for Portable NPWT

Role: lead

NCT02666157Phase 4Unknown

Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation

Role: collaborator

NCT02169258Not ApplicableUnknown

Routine Coronary Catheterization in Low Extremity Artery Disease Undergoing Percutaneous Transluminal Angioplasty

Role: collaborator

All 6 trials loaded